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Abstract 18 
 19 
Despite Blastocystis being one of the most widespread and prevalent 20 
intestinal eukaryotes, its role in health and disease remains elusive. DNA-21 
based detection methods have led to a recognition that the organism is much 22 
more common than previously thought, at least in some geographic regions 23 
and some groups of individuals. Molecular methods have also enabled us to 24 
start categorizing the vast genetic heterogeneity that exists among 25 
Blastocystis isolates, wherein the key to potential differences in the clinical 26 
outcome of Blastocystis carriage may lie. 27 
 28 
In this review we summarize some of the recent developments and advances 29 
in Blastocystis research, including updates on diagnostic methods, molecular 30 
epidemiology, genetic diversity, host specificity, clinical significance, 31 
taxonomy, and genomics. As we are now in the microbiome era, we also 32 
review some of the steps taken towards understanding the place of 33 
Blastocystis in the intestinal microbiota. 34 
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1. INTRODUCTION  43 
 44 
It is now over 100 years since Alexeieff [1] first described the intestinal 45 
eukaryote Blastocystis but, despite the efforts of numerous researchers 46 
(especially in recent years), there are still many unknowns surrounding this 47 
organism. Most important of these is whether Blastocystis causes disease in 48 
humans. For every report linking Blastocystis with gastrointestinal or other 49 
symptoms there is another that finds no such link. There are a number of 50 
factors that have contributed to this apparent lack of progress and these will 51 
form the basis of this review. We would like to warn the reader at this early 52 
stage that we ourselves are convinced only that there are no definitive data 53 
yet available to resolve this issue.   54 
 55 
2. TAXONOMY AND EVOLUTION  56 
 57 
In culture, Blastocystis is generally spherical with no obvious surface features. 58 
When stained, the most common morphological form seen has a large central 59 
vacuole of unknown function and the cytoplasm with all the organelles is 60 
visible as a thin peripheral layer between the vacuole and the cell membrane 61 
(Figure 1). While many morphological forms have been described, the 62 
significance of most is unclear, the boundaries between them are not discrete, 63 
and some may well represent degenerating forms [2]. We refer the reader to 64 
earlier reviews for more details [3-5]. The life-cycle is typical of most gut 65 
protists, with a resistant cyst form for transmission and a trophic form that 66 
divides by binary fission. More complex and alternative life-cycles have been 67 
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described (discussed in [5]) but in our opinion there is no conclusive evidence 68 
for anything other than this simple two-stage cycle. 69 
 70 
Blastocystis has a complicated taxonomic history. It has been viewed as a 71 
fungus, a sporozoan and even the cyst of another organism at various points 72 
in its history, until 20 years ago [6] when it was finally placed among the 73 
Stramenopiles. This is one of the major groups of eukaryotes [7], but one that, 74 
to date, contains only a single other human-infective eukaryote, Pythium. 75 
Blastocystis has none of the typical features of a stramenopile, which is in part 76 
why identifying its correct relationships took so long. 77 
 78 
Since its classification as a Stramenopile further data have emerged 79 
regarding the closest relatives of Blastocystis. These turn out to be poorly 80 
known flagellated or ciliate-like organisms that live in vertebrate intestines. 81 
While most Stramenopiles are free-living and aerobes, Blastocystis and its 82 
relatives are gut-living and anaerobes, although they do have mitochondrion-83 
like organelles (see later). Blastocystis is related specifically to the 84 
Proteromonadidae and Slopalinida [8], but these cannot be considered close 85 
relatives. However, it seems likely that the common ancestor of these groups 86 
of organisms was already living in a gut and an anaerobe. 87 
 88 
The simple spherical morphology of Blastocystis mentioned above applies to 89 
all members of this genus. This means that morphology is of no use in 90 
defining species. Traditionally, Blastocystis species have been defined by the 91 
identity of their host, with all human Blastocystis being assigned to 92 
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Blastocystis hominis. However, even before DNA sequences identified 93 
Blastocystis as a Stramenopile it had become clear that significant 94 
heterogeneity existed among human Blastocystis. Using serology, 95 
isoenzymes and karyotyping, human Blastocystis were being divided into 96 
subgroups [4], and this picture of variation was reinforced by direct and 97 
indirect DNA sequence analyses [9]. Subsequent data have only added to the 98 
diversity and have refined our understanding of this genus. 99 
 100 
Analyses of human Blastocystis by different researchers always resulted in 101 
the detection of variation, but each group came up with its own nomenclature 102 
for the groupings it identified. To resolve this confusion a consensus 103 
terminology was agreed [9] and this classification of human Blastocystis into 104 
numbered subtypes has simplified communication among workers in this field. 105 
At the time of the consensus two things were clear: 1. that humans were host 106 
to a number of distinct small subunit rRNA gene (SSU-rDNA)-based subtypes 107 
of Blastocystis, and 2. that most of these subtypes were also found in other 108 
mammalian or avian hosts. This meant the host-linked binomial species 109 
names were untenable, as the same organism was being called by multiple 110 
names. For example, one grouping of Blastocystis hominis proved to be 111 
genetically indistinguishable from Blastocystis ratti; both are now known as 112 
Blastocystis subtype 4 (ST4). 113 
 114 
The current taxonomy of Blastocystis follows a distinct structure for mammal 115 
and bird organisms compared to all others [10]. The mammalian/avian 116 
Blastocystis are subdivided into seventeen subtypes (STs), nine of which 117 
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(ST1–ST9) have been found in humans. There is host range overlap 118 
observed for many of these organisms (Figure 2). Blastocystis from reptiles, 119 
amphibia and invertebrates retain Linnean binomial names for the most part. 120 
This is largely because little investigation of diversity and host range of these 121 
Blastocystis has been undertaken to date and so the same impetus to change 122 
the nomenclature has not existed. Whether a similar situation involving broad 123 
host-range and large genetic diversity will be uncovered in those organisms 124 
remains to be seen; it seems likely, and therefore the nomenclature of 125 
Blastocystis in those hosts may require a similar solution. 126 
 127 
3. GENETIC DIVERSITY AND HOST SPECIFICITY  128 
 129 
Subtypes of Blastocystis are discrete and no intermediate variants have been 130 
uncovered to date despite extensive sampling from around the world. 131 
However, many host species remain to be sampled, so this picture may 132 
change. Guidance on how and when to define a new subtype has been 133 
published [11]. The recommendation is that a minimum of 5% sequence 134 
divergence from the SSU-rDNA of known subtypes is required before defining 135 
a new subtype is appropriate. One of the reasons for establishing this 136 
boundary is that Blastocystis subtypes are often assigned based on the 137 
sequence with the closest similarity in sequence database searches, without 138 
taking into account the degree of similarity. So a sequence that actually 139 
represents a new subtype may be assigned to an existing subtype. This 140 
misattribution has been a problem in some existing cases, for example ST13, 141 
as discussed in reference [10]. Unfortunately, information attached to entries 142 
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in GenBank databases are rarely corrected and this can result in 143 
misidentifications being propagated forward in the literature. 144 
 145 
The 5% level of divergence to define a new subtype was chosen in part 146 
because variation within subtypes can also be substantial, up to at least 3% 147 
[11]. Therefore a single ‘outlier’ sequence that appears to be distinct and 148 
potentially a new subtype could eventually merge into an adjacent subtype as 149 
more sequences become available. Only as more subtyping data accumulate 150 
will the validity of this arbitrary threshold be tested. Note that 5% divergence is 151 
the recommendation for establishing new subtypes, where sampling is likely 152 
to be limited. The divergence between some existing subtypes (for example, 153 
ST6 and ST9) is actually less than 5%. However, sampling is sufficient to give 154 
us confidence that these are indeed distinct lineages rather than variants of 155 
the same subtype. In other words, 5% divergence has been chosen as quite a 156 
stringent criterion and more data may lead to the revision of new subtype 157 
definitions in the future..  158 
 159 
As mentioned earlier, nine distinct subtypes have been found in humans 160 
(Figure 2). However 95% of human infections sampled belong to one of just 161 
four of these subtypes (STs 1-4; [12]) and only one of the human subtypes 162 
has not yet been found in another host: ST9 can claim (at present) to be 163 
restricted to humans. The four most common STs in humans have also been 164 
detected in other hosts. Most frequently these hosts are other primates, but 165 
they have also been found in various hoofed mammals, rodents and even 166 
birds [10]. Conversely, the rarer subtypes in humans (STs 5-8) are more 167 
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commonly found in other hosts: ST5 in hoofed animals, STs 6 and 7 in birds, 168 
and ST8 in non-human primates. It has been suggested that these rarer 169 
subtypes in humans are of zoonotic origin and there is some evidence to 170 
support this: ST8 has frequently been found in zookeepers that work with non-171 
human primates [13], and ST5 is prevalent in piggery workers in Australia 172 
[14], for example. However, there is no reason to suspect that human 173 
infections involving the common STs (STs 1-4) originate from non-human 174 
sources except in rare cases.  175 
 176 
Exposure to Blastocystis-infected animals alone is not sufficient to result in an 177 
infection. For example, ST10 is very common in livestock [10] but is yet to be 178 
reported in humans. This suggests that variables other than just body 179 
temperature are determining the ability of Blastocystis to colonize the human 180 
gut; the gut flora may have an impact, for example. 181 
 182 
The degree of genetic diversity within subtypes is quite variable. ST3 is 183 
probably the most diverse of the well-studied subtypes – varying by ca. 3% in 184 
the SSU-rDNA sequences - while ST4 shows the least variation, especially in 185 
humans [15]. Diversity in these subtypes has been further explored using a 186 
multi-locus sequence typing approach based on variation in several regions of 187 
the mitochondrion-like organelle’s genome [15]. MLST data are not yet 188 
published for other subtypes. How genetic variability within a subtype is 189 
reflected in phenotypic and functional variability is as yet unclear. However, 190 
differences in adhesion and drug resistance between strains of Blastocystis 191 
ST7 have been reported [16]. 192 
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 193 
Intra-subtype variation has provided further insight into host specificity. For 194 
example, ST3 is common in both humans and non-human primates [13]. 195 
However, MLST analysis divided ST3 into four clades and almost all human 196 
samples fell into only one of these clades [15]. Where this was not the case, 197 
the individuals concerned had work exposure to non-human primates, again 198 
suggesting zoonotic transmission had occurred [15]. It would be interesting to 199 
know whether such host specificity exists between variants within other 200 
subtypes that are found in a wide range of mammals and exhibit genetic 201 
diversity, like ST10 for example [17]. 202 
 203 
MLST has the potential to provide insight into geographic aspects of genetic 204 
variation as well. However, this could be confounded by the increasing 205 
population mobility in today’s world: geographic differences will be starting to 206 
break down. To date, it is only subtyping that has provided evidence of 207 
geographic differences in Blastocystis distribution. Specifically, it has become 208 
clear that ST4 has a restricted distribution, being rare or absent in South 209 
America, North Africa, and the Middle East, while being the second most 210 
common subtype in Europe (summarized in [12]). The reasons for this are 211 
obscure, but when combined with the relatively low genetic diversity of ST4 in 212 
humans the evidence suggests that ST4 may only have entered the human 213 
population relatively recently (perhaps in Europe) and is yet to spread around 214 
the world [12]. ST4 is also found in other hosts [10], but there is no link 215 
between these hosts and Europe. 216 
 217 
10 
 
 218 
4. DIAGNOSIS AND MOLECULAR CHARACTERIZATION 219 
 220 
For most parasites, both direct and indirect diagnostic methods have been 221 
developed. Direct methods include those based on morphology (microscopy) 222 
and detection of DNA (typically PCR) or antigens (IFA, antigen ELISA, etc.), 223 
while indirect methods are based mainly on detection of antibodies [18]. While 224 
the potential utility of serology in the indirect detection of Blastocystis 225 
infections remains unclear, some studies have used serology to look for 226 
quantitative differences in antibody responses between symptomatic and 227 
asymptomatic individuals ([19-20]; see also below). 228 
 229 
With regard to direct detection methods, the use of diverse diagnostic 230 
modalities of varying sensitivity may very well have impaired attempts to 231 
define the role of Blastocystis in health and disease [21-23]. Molecular 232 
methods developed to detect Blastocystis in genomic DNA extracted directly 233 
from fresh stool have highlighted the sensitivity shortcomings of diagnostic 234 
methods such as the traditional ‘ova and parasites’ (O&P) work-up (used to 235 
detect cysts of protozoa and larvae and eggs of helminths), culture methods, 236 
and permanent staining of fixed fecal smears [24-26]. 237 
 238 
Simple stains like Lugol’s iodine can be used as a quick aid to the 239 
identification of Blastocystis in fecal smears or concentrates; the organism is 240 
otherwise difficult to differentiate from other structures seen in unstained 241 
preparations due to the lack of diagnostic morphological features. Trichrome 242 
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staining is one of several permanent stains used for detection of trophic forms 243 
of protozoa in feces. Blastocystis stains characteristically with Trichrome, and 244 
this method had a specificity and sensitivity of 100% and 82%, respectively, in 245 
a study by Stensvold et al. [24].  246 
 247 
Despite being the primary diagnostic tool worldwide, the use of microscopy to 248 
detect Blastocystis has limited utility in clinical microbiology laboratories and 249 
in generating data for clinical and epidemiological purposes: 1) Microscopy of 250 
fecal concentrates - the commonly applied O&P method - has very low 251 
sensitivity in detecting Blastocystis [24, 27]; 2) there is no consensus on the 252 
importance of the cell numbers (see below) or the various morphological 253 
forms reported; and 3) microscopy cannot distinguish between genetically 254 
highly dissimilar organisms (STs), which may differ in their clinical 255 
significance, a situation potentially similar to Entamoeba histolytica and 256 
Entamoeba dispar. Nevertheless, there are situations in which microscopy 257 
may serve a purpose, such as those aiming to verify the presence of 258 
Blastocystis in various types of non-human samples, including those of 259 
environmental and animal origin, to inform hypotheses on transmission. For 260 
instance, a recent study used microscopy to identify Blastocystis in various 261 
environmental samples, including food, water, and fomites [28].  262 
 263 
Xenic in vitro culture (XIVC) is defined as culture in the presence of an 264 
undefined bacterial flora. Blastocystis can be grown and propagated xenically 265 
in a variety of media [29, 30]. Perhaps due to its simplicity and low cost, 266 
Jones’ medium has been popular for both detecting and maintaining 267 
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Blastocystis; another medium often used for isolation is Robinson’s [29], while 268 
we have also used LYSGM (a variant of TYSGM-9; [31]) for propagation when 269 
large numbers of cells are needed. XIVC as a diagnostic tool using Jones’ 270 
medium has a sensitivity ranging from 52%—79% compared with real-time 271 
PCR assays [26, 32].  272 
 273 
The diagnostic utility of Ag-ELISA and immunofluorescent antibody staining 274 
methods for the detection of Blastocystis, including commercial kits such as 275 
ParaFlor B (Boulder Diagnostics, Boulder, CO, USAa), coproELISA™ 276 
Blastocystis (Savyon Diagnostics, Ashdod, Israel), and Blasto-Fluor 277 
(Antibodies Inc., Davis, CA, USA), is as yet unclear, since these assays have 278 
been used in only a limited number of studies and applied to only a very 279 
limited number of samples [33-37]. The utility of such assays remains 280 
unknown as the range of subtypes they detect is unclear.  281 
 282 
The first diagnostic PCR for Blastocystis was introduced in 2006 [25] but it 283 
was later suspected to exhibit preferential amplification of some subtypes over 284 
others. Since then, three diagnostic real-time PCR assays have been 285 
reported. A real-time PCR based on an unknown Blastocystis target using 286 
FRET probes was validated against ST1, ST3, and ST4 [38]. A SYBR green 287 
real-time PCR used the SSU rRNA gene for detection of Blastocystis-specific 288 
DNA (ST1–ST9), and subsequent subtyping was performed by melting curve 289 
analysis [26]. The relatively large PCR product used (320 to 342 bp, 290 
depending on the subtype) may impair the sensitivity of this test—especially 291 
when DNA quality is not optimal—and the specificity of the assay was 95%. 292 
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The third real-time assay, using a hydrolysis probe based on the SSU rRNA 293 
gene, was characterized by 100% specificity and ability to detect all nine 294 
subtypes identified in humans so far [32]. The use of real-time PCR in large-295 
scale surveys would assist in identifying whether the development of 296 
symptoms is related to infection intensity by simple analysis of threshold cycle 297 
(Ct) values for individual samples, as this enables quantitation of the amount 298 
of Blastocystis-specific DNA present. The same DNA samples may also be 299 
used for subtyping and MLST protocols, hence allowing the detection and 300 
evaluation of genetic diversity as well as the simple presence of Blastocystis 301 
[22]. Blastocystis has also been included as a diagnostic target in commercial 302 
gastrointestinal pathogen diagnostic panels such as Feconomics® (Salubris 303 
Inc, Boston, USA), EasyScreen™ Enteric Parasite Detection Kit (Genetic 304 
Signatures, Sydney, Australia), and NanoChip® (Savyon Diagnostics, Israel). 305 
 306 
While the potency of DNA-based methods is evident, they do not allow the 307 
evaluation of whether differences in morphotypes are important. Several 308 
different forms of Blastocystis have been described, including the avacuolar, 309 
vacuolar, multivacuolar, granular, ameboid, and cyst stages. Although there 310 
are a few reports of ameboid stages being detected only in symptomatic 311 
Blastocystis carriers [eg. [39]), there is no consensus regarding the 312 
significance of the different forms. Moreover, as mentioned earlier, it is not 313 
clear whether some of these forms represent life-cycle stages, or are artifacts 314 
resulting from exposure to oxygen or other stresses [2]. Relatively few studies 315 
on the cyst stage are available [40-42], which is remarkable given that this is 316 
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the stage that allows survival of the parasite in the environment and 317 
transmission to a new host. 318 
 319 
The high sensitivity of qualitative PCR for detection of Blastocystis DNA in 320 
stool was reinforced by a recent study of Blastocystis in Senegalese children 321 
[43], where the prevalence of Blastocystis among 93 children with and without 322 
gastrointestinal symptoms was 100%. When prevalence is so high there will 323 
be little incentive for including Blastocystis PCR as a screening tool in the 324 
clinical microbiology laboratory. However, where treatment of a patient with 325 
Blastocystis has been undertaken, PCR methods are useful in post-treatment 326 
follow-up to evaluate treatment efficacy.  327 
 328 
This leads to one of the fundamental questions for clinical microbiology labs: 329 
When is testing for Blastocystis appropriate? Data currently emerging indicate 330 
that Blastocystis can be more common in individuals with a healthy GI system 331 
than in patients with organic and functional bowel diseases (see below). 332 
Therefore, the inclusion of Blastocystis as a specific target in screening 333 
panels, alongside known pathogens such as Giardia, Cryptosporidium, and 334 
Entamoeba histolytica, currently appears to make little sense in the clinical 335 
microbiology laboratory. The presence of Blastocystis in stool samples most 336 
likely implies that the carrier has been exposed to fecal-oral contamination, 337 
which should prompt the laboratory to look more closely for the presence of 338 
pathogens transmitted in the same way. However, since Blastocystis may 339 
colonize the human colon for more than 10 years [44], it may be impossible to 340 
identify when this contamination happened. This has important implications 341 
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for the interpretation of clinical microbiology lab results. Blastocystis is 342 
sometimes detected in stool samples of patients with diarrhea or other 343 
gastrointestinal symptoms and in the absence of proven pathogens, so 344 
clinicians might conclude that Blastocystis could be the cause of the 345 
symptoms. If it is known that the infection is recent, the organism could 346 
certainly be viewed as a potential cause of the symptoms; however, in most 347 
cases it will be impossible to rule out that it has been present in the gut for 348 
months - even years - and therefore is an incidental finding.  349 
 350 
Another dilemma is the question of whether or not to report the presence of 351 
Blastocystis in stool samples given that it is so common. Several studies have 352 
sought to address this by setting a threshold number of Blastocystis 353 
organisms detected microscopically per visual field at a specified 354 
magnification before scoring the sample as positive; usually this has been set 355 
at 5 organisms per 40x field (see references in [5]). However, the rationale for 356 
this is unclear. It is known that shedding of both trophic and cyst forms of the 357 
organism is irregular [45]. Moreover, several factors may influence the 358 
number of organisms seen per visual field, including whether or not the 359 
sample was fresh or preserved prior to analysis, and if preserved whether or 360 
not the sample was fresh at the time of fixation. Real-time PCR would be 361 
more sensitive and less affected by some of these variables. 362 
 363 
In the event that symptoms are eventually linked to specific subtypes, 364 
including those individual subtypes as specific targets in diagnostic panels 365 
would be more relevant than including a general target for Blastocystis. 366 
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Subtype-specific PCRs already exist, and barcoding of Blastocystis DNA 367 
amplified by generic primers can also be performed [46, 47]. To date, 368 
diagnostic PCR methods have been developed and validated only for human 369 
clinical samples; no validated PCR method for detecting Blastocystis in 370 
environmental samples is yet available to the knowledge of the authors. 371 
 372 
Given the extensive cryptic genetic diversity of Blastocystis [10, 15, 48], a 373 
number of tools have been developed to map its molecular epidemiology. 374 
Among these tools, two in particular have been widely used. A PCR assay for 375 
detecting subtypes using sequence-tagged-site (STS) primers was developed 376 
and refined in the early 1990s [49]. This approach involves the use of seven 377 
PCR reactions, one for each of subtypes 1—7, and should be viewed as 378 
comprising a diagnostic method for each of these subtypes, circumventing the 379 
need for sequencing. The other method involves analysis of SSU rDNA 380 
variation. This approach has been developed independently by several 381 
groups, each of which used different regions of the SSU rRNA gene as 382 
markers [24-25, 50-56]. The barcoding method mentioned above, developed 383 
in 2006 by Scicluna et al., is one such example [46]. A comparison of the STS 384 
method and barcoding showed that barcoding should be preferred where 385 
possible for a variety of reasons [47]. First and foremost, barcoding enables 386 
the detection of subtypes beyond STs 1—7 and further scrutiny of genetic 387 
diversity. The barcode region has also been validated as a marker of overall 388 
genetic diversity of Blastocystis [15].  389 
 390 
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Barcoding uses the primers RD5 and BhRDr, which amplify ~600 bp at the 5’-391 
end of the SSU rRNA gene. Comparison of phylogenetic trees obtained by 392 
analysis of barcoding sequences with those obtained using concatenated 393 
sequences obtained by MLST (reflecting loci in the genome of the 394 
mitochondrion-like organelle) demonstrated the appropriateness of using the 395 
barcode region as a surrogate marker for overall genome diversity in this 396 
particular organism [15]. The drawbacks of barcoding compared to the STS 397 
method are that sequencing is required and that mixed subtype infections 398 
may not always be evident in sequence chromatograms, and, even if they are, 399 
they may prove difficult to decipher [47]. On the other hand, barcoding 400 
enables more subtle analyses, namely SSU rDNA allele analysis [15]. A 401 
public database is available (http://pubmlst.org/blastocystis/) that includes a 402 
sequence repository for barcode sequences and those obtained by MLST. It 403 
also has a BLAST facility, where individual or bulk fasta files can be uploaded 404 
and analyzed for rapid identification of subtype and allele number, hence 405 
eliminating the need for phylogenetic analysis. To date, 35 SSU rDNA alleles 406 
within ST3 have been identified, whereas the number of SSU rDNA alleles for 407 
ST4 and some other subtypes remains much more limited. However, some of 408 
the allelic variation included is the result of sequencing of cloned DNA; 409 
intragenomic SSU rDNA polymorphism has been reported [57, 58], and such 410 
polymorphism will likely go unnoticed when sequences obtained directly from 411 
PCR products are studied. 412 
 413 
There is no doubt that DNA-based methods now enable us to carry out large 414 
and well-designed research studies that are dependent on accurate detection 415 
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and molecular characterization of Blastocystis. Such studies are required to 416 
produce data that can shed light on the role of this organism in human health 417 
and disease with a view to potentially developing diagnostics, biomarkers, and 418 
therapies, including antimicrobial or probiotic agents, as appropriate.  419 
 420 
5. CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY 421 
 422 
Even after more than 100 years, the role of Blastocystis in human health and 423 
disease remains obscure. While Blastocystis has been speculated to be 424 
involved in a range of organic and functional bowel diseases, it is clear that 425 
asymptomatic carriage is common. This does not mean that Blastocystis does 426 
not cause disease. The situation may resemble that for Giardia, where many 427 
infections are asymptomatic (for example [59]), and Entamoeba histolytica, 428 
where the proportion of symptomatic infections is at most 10% [60]. Case 429 
reports and surveys continue to be published with regularity, mostly indicating 430 
a link between Blastocystis and symptoms, although not always. We do not 431 
propose to evaluate all the evidence here. However we do wish to highlight 432 
two common issues: 1. Identification of an appropriate control group for 433 
survey studies can be problematic; and 2. Excluding all other possible 434 
etiologic agents or non-infectious causes of intestinal symptoms is almost 435 
impossible. 436 
 437 
While distinctive intestinal pathology has been clearly linked to the intestinal 438 
protists Giardia, Cryptosporidium, and Entamoeba, there is little – if any – 439 
evidence for direct pathology caused by Blastocystis. Phagocytosis of red 440 
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blood cells is a well-known feature of Entamoeba histolytica that correlates 441 
with virulence; there is only one study reporting phagocytosis in Blastocystis 442 
[61]. No Blastocystis proteins such as glycoproteins or lectins that could 443 
facilitate attachment to the gut epithelial layer have been identified, although 444 
Denoeud et al. [57] have speculated that Blastocystis hydrolases might be 445 
able to alter the colonic mucus layer (see below). It is generally accepted that 446 
Blastocystis is non-invasive as well as lacking the ability to phagocytize the 447 
microbiota or host-derived material.  448 
 449 
When examining tissue sections from pig intestines, Fayer et al. [62] found 450 
Blastocystis primarily in the lumen, usually associated with digested food 451 
debris, and although sometimes in close proximity to or appearing to adhere 452 
to the epithelium, there were no cells penetrating to the epithelium or the 453 
lamina propria. These observations were confirmed by Wang et al. [63], who 454 
did not observe any obvious pathology in histological sections of porcine gut 455 
mucosal biopsies. In the latter study, Blastocystis cells were observed as 456 
vacuolar/granular forms found within luminal material or in close proximity to 457 
epithelial cells, with no evidence of attachment or invasion. When Blastocystis 458 
is observed adhering to the epithelium in histological preparations it should be 459 
kept in mind that histological procedures are likely to dissolve and eliminate 460 
the mucus layer that is potentially separating Blastocystis from the mucosa in 461 
vivo. 462 
 463 
Despite the absence of invasion, discrete non-specific colonic inflammation 464 
has been reported in a patient with both urticaria and what was characterized 465 
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as ‘heavy Blastocystis colonization’; Blastocystis eradication resulted in 466 
symptom resolution [64]. There are also some reports of Blastocystis having 467 
been found extra-intestinally, but in those cases it has not been possible to 468 
rule out that the presence of Blastocystis at these sites was merely a result of 469 
incidental or secondary colonization resulting from damage generated by 470 
other microorganisms or anatomical anomalies [65-68]. 471 
 472 
Blastocystis is one of several organisms to have been linked to Irritable Bowel 473 
Syndrome (IBS), including post-infectious IBS [69-71]. Genome analysis by 474 
Poirier et al. [72] identified various genes encoding hydrolases and serine and 475 
cysteine proteases, and the authors speculated that these potential virulence 476 
factors could be triggers of IBS by alteration of the mucus layer and 477 
interaction with tight junctions. 478 
 479 
Cross-sectional studies testing the hypothesis that Blastocystis is linked to 480 
IBS mostly assume that, if the organism is associated with the disease, it 481 
should be more common in patients with IBS symptoms. The outcomes of 482 
such studies have been mixed, with some finding a higher prevalence of 483 
Blastocystis in IBS patients and some finding no difference or even lower 484 
prevalence (summarized in [12]). A few have looked at the subtype 485 
distribution, but although they have generally found differences between IBS 486 
and non-IBS patients, there is no consistency regarding the subtypes 487 
associated with IBS (summarized in [12]). IBS itself presents a diverse 488 
picture, with patients having diarrhea, constipation or a mixture of symptoms 489 
21 
 
[69]. Even fewer investigations have been performed to look at potential links 490 
between Blastocystis and subgroups within IBS. 491 
 492 
IBS patients are likely to have multiple tests performed before a diagnosis is 493 
made and, because of this, a common finding may well be Blastocystis in the 494 
stool, which might then be suspected of being the agent responsible for the 495 
symptoms if no other candidates have been uncovered. So Blastocystis may 496 
be more commonly detected in IBS patients simply because the investigations 497 
are more thorough. Post-infectious IBS - a term describing the development of 498 
IBS following treatment of an infection with antimicrobials [71] – adds another 499 
complication, as the actual trigger for IBS may have been eliminated by 500 
antimicrobial treatment, leaving Blastocystis behind to take the blame. It is 501 
also impossible to exclude that Blastocystis was the initial trigger of IBS even 502 
if it is no longer present. The potential links, if any, between Blastocystis and 503 
IBS may be impossible to prove or disprove without large longitudinal cohort 504 
studies.  505 
 506 
One of the most interesting recent findings is that Blastocystis could be a 507 
marker of gastrointestinal health rather than a cause of disease. This may in 508 
fact not be surprising, given that we have been unable to reach a consensus 509 
on a role for the organism in disease despite the large number and wide 510 
range of investigations undertaken. A recent study identified Blastocystis as a 511 
common member of the healthy human gut microbiota, with greater than 50% 512 
of the healthy background population colonized [44]. Moreover, long-term 513 
colonization trends were also noted; the same strains were present in the 514 
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same hosts for up to 10 years [44]. A lower prevalence of Blastocystis in IBS 515 
patients (n = 189) compared with healthy controls (n = 297), 14.5% versus 516 
22% respectively (p = 0.09), was also highlighted in a recent study [73]; the 517 
prevalence of Dientamoeba fragilis also differed significantly between the two 518 
groups, with D. fragilis being similarly more common in individuals without 519 
gastrointestinal symptoms. Another study, this time involving 96 healthy 520 
controls and 100 patients with Inflammatory Bowel Disease (IBD) - a disease 521 
affecting about 12,000 individuals in Denmark alone, 0.2% of the population - 522 
detected a significantly lower prevalence of Blastocystis in IBD patients 523 
compared with healthy controls (p < 0.05), with only 5/100 IBD patients being 524 
colonized by Blastocystis compared with 18/96 controls [74-75]. Interestingly, 525 
four of the five positive IBD patients were in an inactive stage of the disease; 526 
only 1/42 patients with active IBD was a carrier.  527 
 528 
Whether it is linked to gastrointestinal health or disease, it is clear that 529 
Blastocystis is much more common than previously reported, reaching a 530 
prevalence of 100% in some cohorts [43]. Individuals in communities with high 531 
prevalence may become and remain infected from a very young age, while in 532 
other communities, particularly where the overall prevalence is low, many 533 
individuals may acquire Blastocystis later in life. For now, it is uncertain 534 
whether the age at colonization - including whether Blastocystis becomes a 535 
stable member of the intestinal microbiota from early on - is of any clinical 536 
importance. It could be that in some regions of the world, Blastocystis might 537 
be an ‘emerging pathogen’.  538 
 539 
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While recent observations suggest that Blastocystis colonization may be 540 
inversely correlated with intestinal disease [44], we now know that the 541 
bacterial component of the gut microbiota in IBS, IBD, and other intestinal 542 
diseases is significantly different to that of the healthy human gut [69, 76]. 543 
Importantly, this may in fact indicate that Blastocystis is dependent on other 544 
components of the microbiota to colonize and maintain a stable colonization in 545 
the human gut. To test this prediction, we recently obtained access to data 546 
from the MetaHIT Consortium (http://www.metahit.eu/), originally generated to 547 
identify associations between intestinal bacterial communities and disease 548 
patterns, including obesity, diabetes, and IBD [77]. From the data, we were 549 
able to extract Blastocystis-specific DNA signatures, which enabled us to (1) 550 
identify the relative prevalence of Blastocystis in each of the study groups, 551 
and (2) to perform a preliminary investigation of the association between 552 
Blastocystis and bacterial communities, in this case the so-called 553 
‘enterotypes’ [77]. Our analysis [78] showed that: 1) Blastocystis was indeed 554 
negatively associated with disease and absent in all 13 patients with Crohn’s 555 
disease (although not all studies have found this; [79]); and 2) very 556 
intriguingly, Blastocystis was negatively associated with the Bacteroides 557 
enterotype (p < 0.0001, unpublished data). This finding may be linked to the 558 
fact that the Bacteroides enterotype—compared with the Prevotella and the 559 
Ruminococcus enterotypes—is characterized by low microbial diversity, and 560 
this could therefore indicate that Blastocystis requires high overall microbial 561 
diversity to become established in the human colon. However, it could also be 562 
that some other unknown feature(s) of the enterotype may be responsible for 563 
determining Blastocystis colonization, such as bacterial metabolic by-564 
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products. There is no doubt that studies of Blastocystis in the context of 565 
intestinal bacterial communities and host physiology and immunity are likely to 566 
advance our understanding of the clinical significance of Blastocystis. The 567 
apparent impact of the gut flora on Blastocystis colonization may also mean 568 
that standard animal models may be of limited use in exploring the effects of 569 
Blastocystis on the human gut. 570 
 571 
Comparing both bacterial and eukaryotic microbial communities in samples 572 
from 23 individuals from agrarian communities in Malawi following traditional 573 
lifestyles and from 13 individuals residing in Pennsylvania and Colorado, 574 
USA, following a modern lifestyle, Parfrey et al. [80] recently showed that the 575 
Malawi population harbored a diverse community of protists, including 576 
Blastocystis, when compared to the North American populations, and that the 577 
overall organismal diversity in the Malawian human gut is comparable to that 578 
in other mammals. These, and other, data could indicate that the declining 579 
diversity of the human bacterial microbiota identified in the West compared 580 
with populations with traditional agrarian lifestyle has led to a reduced 581 
prevalence of Blastocystis in Western populations [81]. 582 
 583 
It is also clear that geographical differences in subtype distributions may result 584 
in geographical differences in the clinical significance of the parasite. There is 585 
precedent in Entamoeba for cryptic genetic differences underlying differences 586 
in the clinical outcome of infection (the E. histolytica/E. dispar story; [60]). So 587 
a working hypothesis over the past few years has been that differences 588 
between the clinical outcome of Blastocystis infection may reflect genetic 589 
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differences in the organism. Hence, dozens of studies from all over the world 590 
have sought to identify Blastocystis STs in both healthy and symptomatic 591 
individuals (summarized in [11]). The distribution of subtypes across the major 592 
geographical regions is depicted in Figure 3. So far, no particular subtype has 593 
been linked consistently to disease. However, such a finding might not be 594 
unexpected if the distribution of subtypes is uneven. While ST1, ST2, and ST3 595 
appear to have a global distribution, current data suggest that ST4 is confined 596 
mainly to Europe. ST4 was the only subtype identified in Danish patients with 597 
acute diarrhea, but the overall prevalence of the parasite was also lower in 598 
this group of patients than in others that have been studied in Denmark [82]. 599 
ST4 also dominated in symptomatic patients in Spain [83]. 600 
 601 
A significant gap in clinical Blastocystis research is the lack of large 602 
randomized controlled clinical treatment trials [84-87]. To date these have 603 
produced inconsistent and indeed contradictory results. It appears that no 604 
single drug or drug combination currently in use consistently results in reliable 605 
Blastocystis eradication [88-90]. Metronidazole has traditionally been used to 606 
treat anaerobic microorganisms, including Entamoeba and Giardia; however, 607 
its effect on Blastocystis has in some studies been minimal, with an 608 
eradication rate as low as 0%. Even the use of combinations such as 609 
diloxanide furoate, secnidazole, and trimethoprim/sulfamethoxazole or 610 
nitazoxanide may not result in consistent eradication [90]. 611 
 612 
 613 
6. GENOMICS 614 
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 615 
With the advances in sequencing technology in recent years it has become 616 
possible to sequence eukaryotic genomes quickly and relatively inexpensively 617 
compared with even a few years ago. Perhaps surprisingly, the published 618 
Blastocystis nuclear genome sequences at the time of writing are for ST7, 619 
obtained by ‘traditional’ Sanger sequencing [57], and ST4, obtained by next 620 
generation sequencing [91]. Others have not yet appeared in print despite 621 
anecdotal evidence that suggests a flood of new data is about to arrive. 622 
 623 
However, Blastocystis has two genomes. In addition to the nuclear genome it 624 
also contains an organelle genome. In contrast to most anaerobic eukaryotes, 625 
Blastocystis has mitochondrion-like organelles that have a quite normal 626 
appearance under the transmission electron microscope (see [4]). It was 627 
known for many years that these organelles contained DNA, based on 628 
staining properties, but it was not until 2007 that the coding potential of these 629 
molecules was uncovered. Two groups published sequences of the genomes 630 
present in the mitochondrion-like organelle in three subtypes – STs 1, 4 and 7 631 
[92-93]. The gene content and gene order of the 27-29 kilobasepair circular 632 
molecules was identical, although the sequence divergence was 633 
considerable. Subsequently, mitochondrion-like organelle genomes from 634 
additional subtypes have been obtained (unpublished data) and these initial 635 
observations have been upheld.  636 
 637 
The gene content of the genome of the mitochondrion-like organelle is distinct 638 
from the more familiar ones from mammals and yeast. Particularly notable is 639 
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the absence of any genes encoding cytochrome and ATPase subunits and 640 
the presence of a number of ribosomal protein genes. In common are the 641 
genes encoding ribosomal RNAs and several tRNAs plus NADH 642 
dehydrogenase (Complex I) subunits. The nuclear genomes and expressed 643 
sequence tag (EST) surveys that are available confirm that the Blastocystis 644 
mitochondrion-like organelle has only retained complexes I and II of the 645 
electron transport chain, a characteristic shared with certain other anaerobic 646 
eukaryotes. However, many other features of mitochondrial metabolism are 647 
also present [31, 57]. This is in contrast to the situation in, for example, 648 
Giardia and Entamoeba where the genome has been lost completely and the 649 
function of the resulting organelles (known as mitosomes) has become highly 650 
reduced. Whether the Blastocystis organelle would follow a similar path given 651 
enough time is impossible to predict.  652 
 653 
The only published nuclear genomes at this time are for ST4 and ST7. 654 
However, a recently published report on polyadenylation in Blastocystis also 655 
includes data on a ST1 genome, suggesting its publication is imminent. The 656 
polyadenylation report uncovered a unique situation in Blastocystis, where 657 
around 15% of the stop codons in messenger RNAs are created through the 658 
cleavage of a precursor and addition of the poly A tail to the mRNA [94]. This 659 
is unprecedented outside of mitochondria. Given the degree of genetic 660 
divergence between subtypes, comparative genomics may well reveal 661 
significant differences between features of their nuclear genomes as well as 662 
confirming genus-wide peculiarities, as in this case. 663 
 664 
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Overall, the Blastocystis nuclear genome is quite small (under 19 Mb) with 665 
relatively few genes (just over 6,000), quite a few of which appear to have 666 
been acquired by horizontal gene transfer. Introns are numerous and small, 667 
but repetitive DNA is rare. Of note is the fact that individual ribosomal RNA 668 
cistrons are sometimes present in subtelomeric regions of the genome rather 669 
than being exclusively found in long tandem arrays as in many other 670 
eukaryotes [57].  671 
 672 
7. CONCLUSION  673 
 674 
Blastocystis is one of the most successful intestinal eukaryotes identified to 675 
date, being able to infect a wide range of host species. It may reside in the gut 676 
for years on end and appears to show remarkably little susceptibility to 677 
standard chemotherapeutic interventions, although analysis of biochemical 678 
pathways identified through genome sequencing may generate some new 679 
directions for drug interventions. However, the recognition of a high 680 
prevalence of Blastocystis in healthy populations, identified using sensitive 681 
molecular diagnostic tools, has heralded a paradigm shift in clinical 682 
Blastocystis research. Studies of the gut microbiota in people with and without 683 
Blastocystis are likely to provide valuable - if not critical - information to help 684 
determine the role of Blastocystis in human health and disease.  685 
 686 
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Figure 1. Light microscopy images of Blastocystis. A. Blastocystis in culture.  1047 
Using Robinson’s and other media [29], Blastocystis often reaches high 1048 
density in xenic culture. This stage is typically reported as ‘vacuolar’ due to 1049 
the large central region of uncertain function. Organelles are seen as ‘dots’ 1050 
along the periphery of the cell. B and C. Blastocystis in fecal smears, stained 1051 
using iron-hematoxylin. Prominent nuclei are seen in the periphery of the cells 1052 
as the most conspicuous morphological hallmark, along with the large central 1053 
‘void’. Other organelles can be discerned as smaller peripheral ‘dots’, which 1054 
will include the mitochondrion-like organelles, etc. However, these can only be 1055 
positively identified by transmission electron microscopy. Images courtesy of 1056 
John Williams (A) and Claire Rogers (B, C), Diagnostic Parasitology 1057 
Laboratory, London School of Hygiene and Tropical Medicine. 1058 
 1059 
1060 
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Figure 2. Host range and relative prevalence of Blastocystis subtypes. In this 1061 
schematic, the range of subtypes reported for four major host groups 1062 
(humans, non-human primates, ungulates and birds) is shown. In the circle, 1063 
the numbers are those of the most common subtypes found in the respective 1064 
host, with the integer font size proportional to its prevalence. Numbers in the 1065 
magnified boxes represent those subtypes that each constitute less than 5% 1066 
of the total samples subtyped to date. Derived from the numbers presented in 1067 
reference [10]. As an indication, prevalence figures for STs 1-4 in humans are 1068 
28.0%, 10.9%, 44.4% and 10.0% respectively. 1069 
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Figure 3: Pie charts of human Blastocystis subtype distributions in Europe (A) 1071 
and the rest of the world (B). These were produced from the data presented in 1072 
Alfellani et al. [12]. Of note is the fact that although ST4 accounted for 10% of 1073 
the samples across the world (N = 318), 87% of these (278) were from 1074 
Europe, suggesting that ST4 is more or less geographically restricted to 1075 
Europe. 1076 
 1077 
